Table of Contents Table of Contents
Previous Page  33 / 94 Next Page
Show Menu
Previous Page 33 / 94 Next Page
Page Background


NCCN Guidelines for Patients


Hodgkin Lymphoma, Version 1.2015


Overview of cancer treatments Targeted therapy

Targeted therapy

Targeted therapy is a class of drugs that stops the

action of molecules that help cancer cells grow. It is

less likely to harm normal cells than chemotherapy. At

this time, targeted therapy is not widely used to treat

Hodgkin lymphoma. The drugs approved for certain

people are:

Brentuximab vedotin

Brentuximab vedotin is a targeted therapy that

delivers cell-specific chemotherapy. On the surface

of Hodgkin lymphoma cells are proteins called CD30.

Brentuximab attaches to CD30 and enters cancer

cells. Once inside, it releases the chemotherapy.

By targeting only cells with CD30 receptors, fewer

normal cells are harmed.

Brentuximab vedotin is a treatment option for

classical Hodgkin lymphoma that didn’t respond well

to first-time treatment or that has relapsed. It is also

sometimes given after stem cell transplant. Read

Parts 4.3 and 4.4 for more information. It is slowly

injected into a vein for about 30 minutes. It is often

given every 3 weeks.

The most common side effects include fatigue, low

blood counts, tingling in hands and feet, nausea,

diarrhea, fever, rash, and lung infections. Rare

but severe effects include brain infection, serious

disorder of skin and mucous membranes, and kidney



Inside of cells are protein kinases, called mTor.

Protein kinases are molecules that move chemicals,

called phosphates, from one molecule to another. The

phosphate “turns on” the second molecule.

Everolimus stops mTor from transferring the

phosphate. This action stops the cell from receiving

signals to grow. Everolimus is only an option for

classical Hodgkin lymphoma that was not cured by

first-time treatment. It is made in pill form. It is taken

around the same time every day.

Common side effects include diarrhea, tiredness,

mouth sores, skin rash, cough, and low blood counts.

Serious side effects include other cancers, lung

problems, infections, and kidney failure. Ask your

treatment team for a full list of side effects.


Nodular lymphocyte-predominant Hodgkin lymphoma

is a B-cell lymphoma. On the surface of B-cells are

proteins called CD20. Rituximab attaches to CD20

causing the immune system to attack and kill the


Rituximab is not used alone to treat nodular

lymphocyte-predominant Hodgkin lymphoma. It is

added to chemotherapy. It is a liquid that is injected

into a vein.